MX2015012363A - Compuestos novedosos de pidimidina y piridina y su uso. - Google Patents

Compuestos novedosos de pidimidina y piridina y su uso.

Info

Publication number
MX2015012363A
MX2015012363A MX2015012363A MX2015012363A MX2015012363A MX 2015012363 A MX2015012363 A MX 2015012363A MX 2015012363 A MX2015012363 A MX 2015012363A MX 2015012363 A MX2015012363 A MX 2015012363A MX 2015012363 A MX2015012363 A MX 2015012363A
Authority
MX
Mexico
Prior art keywords
pyridine compounds
usage
novel pyrimidine
pyrimidine
novel
Prior art date
Application number
MX2015012363A
Other languages
English (en)
Other versions
MX363397B (es
Inventor
Wei-Guo Su
Weihan Zhang
Jin Shui Li
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2015012363A publication Critical patent/MX2015012363A/es
Publication of MX363397B publication Critical patent/MX363397B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de pirimidina y piridina de la formula (I) o una sal farmaceuticamente aceptable del mismo, (ver Fórmula) en donde R1, R2, R3, R4, R5, X, Y y G son como se definen en la descripción, para las composiciones farmaceuticas que los contienen, un proceso para la preparación de los mismos, y su uso en la terapia de una enfermedad sensible a la inhibición de FGFR, por ejemplo, cáncer.
MX2015012363A 2013-03-15 2014-03-14 Compuestos novedosos de pirimidina y piridina y su uso. MX363397B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/072690 WO2014139145A1 (en) 2013-03-15 2013-03-15 Novel pyrimidine and pyridine compounds and usage thereof
PCT/CN2014/073444 WO2014139465A1 (en) 2013-03-15 2014-03-14 Novel pyrimidine and pyridine compounds and their usage

Publications (2)

Publication Number Publication Date
MX2015012363A true MX2015012363A (es) 2016-02-03
MX363397B MX363397B (es) 2019-03-21

Family

ID=51535826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012363A MX363397B (es) 2013-03-15 2014-03-14 Compuestos novedosos de pirimidina y piridina y su uso.

Country Status (32)

Country Link
US (2) US20160052926A1 (es)
EP (1) EP2970120B1 (es)
JP (1) JP6109969B2 (es)
KR (1) KR101697982B1 (es)
CN (1) CN105143185B (es)
AR (1) AR095430A1 (es)
AU (1) AU2014231437B2 (es)
BR (1) BR112015020772B1 (es)
CA (1) CA2900748C (es)
CL (1) CL2015002520A1 (es)
CY (1) CY1121804T1 (es)
DK (1) DK2970120T3 (es)
EA (1) EA028654B1 (es)
ES (1) ES2697697T3 (es)
HK (1) HK1212687A1 (es)
HR (1) HRP20181906T1 (es)
IL (1) IL240790B (es)
LT (1) LT2970120T (es)
MX (1) MX363397B (es)
MY (1) MY192641A (es)
NZ (1) NZ711460A (es)
PE (1) PE20151601A1 (es)
PH (1) PH12015502047A1 (es)
PL (1) PL2970120T3 (es)
PT (1) PT2970120T (es)
RS (1) RS58136B1 (es)
SG (1) SG11201506280SA (es)
SI (1) SI2970120T1 (es)
TW (1) TWI618698B (es)
UA (1) UA113470C2 (es)
WO (2) WO2014139145A1 (es)
ZA (1) ZA201505999B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072714A1 (en) 2012-11-07 2014-05-15 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
KR102403306B1 (ko) 2013-01-15 2022-06-02 인사이트 홀딩스 코포레이션 Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물
AU2014264370B2 (en) 2013-05-10 2017-12-14 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
JP2016528298A (ja) 2013-08-23 2016-09-15 インサイト・コーポレイションIncyte Corporation Pimキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2018072707A1 (zh) * 2016-10-18 2018-04-26 保诺科技(北京)有限公司 芳香族醚类衍生物、其制备方法及其在医药上的应用
MX2019005723A (es) * 2016-11-17 2019-10-21 Guangdong Zhongsheng Pharmaceutical Co Ltd Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
CN108503593B (zh) * 2017-02-28 2021-04-27 暨南大学 2-氨基嘧啶类化合物及其应用
CN108570032B (zh) * 2017-03-09 2021-04-02 华东理工大学 新型罗丹明染料及其在抗致病菌中的应用
CN107382836A (zh) * 2017-08-04 2017-11-24 吴赣药业(苏州)有限公司 一种1‑(4‑氨基苯基)‑1h‑吡啶‑2‑酮的制备方法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
BR112022007035A2 (pt) 2019-10-14 2022-06-28 Hutchison Medipharma Ltd Sais de um composto e formas cristalinas dos mesmos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
CN101155799A (zh) * 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
WO2008008234A1 (en) * 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
AU2009261683A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
CA2750086C (en) * 2009-01-28 2018-01-02 Karus Therapeutics Limited Scriptaid isosteres and their use in therapy
PL2821402T3 (pl) 2012-02-28 2020-01-31 Astellas Pharma Inc. Zawierające atom azotu aromatyczne związki heterocykliczne
KR20200046135A (ko) 2012-03-08 2020-05-06 아스테라스 세이야쿠 가부시키가이샤 신규 fgfr3 융합체

Also Published As

Publication number Publication date
CN105143185B (zh) 2018-02-13
WO2014139465A1 (en) 2014-09-18
AU2014231437B2 (en) 2016-11-17
JP2016510774A (ja) 2016-04-11
UA113470C2 (xx) 2017-01-25
CN105143185A (zh) 2015-12-09
CY1121804T1 (el) 2020-07-31
TWI618698B (zh) 2018-03-21
LT2970120T (lt) 2019-01-10
MY192641A (en) 2022-08-29
AU2014231437A1 (en) 2015-09-03
RS58136B1 (sr) 2019-02-28
TW201439064A (zh) 2014-10-16
CA2900748A1 (en) 2014-09-18
SI2970120T1 (sl) 2019-02-28
PH12015502047B1 (en) 2016-01-18
HRP20181906T1 (hr) 2019-02-22
CL2015002520A1 (es) 2016-03-28
EP2970120A4 (en) 2016-08-31
IL240790B (en) 2019-10-31
PE20151601A1 (es) 2015-11-02
BR112015020772A2 (pt) 2017-07-18
US20160024021A1 (en) 2016-01-28
US9701680B2 (en) 2017-07-11
EA201591301A1 (ru) 2016-03-31
PH12015502047A1 (en) 2016-01-18
BR112015020772B1 (pt) 2022-06-07
JP6109969B2 (ja) 2017-04-05
KR20150126391A (ko) 2015-11-11
HK1212687A1 (zh) 2016-06-17
SG11201506280SA (en) 2015-09-29
EA028654B1 (ru) 2017-12-29
ES2697697T3 (es) 2019-01-25
PL2970120T3 (pl) 2019-03-29
MX363397B (es) 2019-03-21
EP2970120A1 (en) 2016-01-20
US20160052926A1 (en) 2016-02-25
PT2970120T (pt) 2018-11-27
EP2970120B1 (en) 2018-09-12
KR101697982B1 (ko) 2017-01-19
NZ711460A (en) 2019-05-31
CA2900748C (en) 2017-10-17
ZA201505999B (en) 2017-11-29
WO2014139145A1 (en) 2014-09-18
IL240790A0 (en) 2015-10-29
AR095430A1 (es) 2015-10-14
DK2970120T3 (en) 2018-12-10

Similar Documents

Publication Publication Date Title
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
PH12017502246A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
MD20140137A2 (ro) Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
MD4664C9 (ro) Lactame aril şi heteroaril condensate
JO3160B1 (ar) مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
MX2013010898A (es) Novedoso derivados de la pirimidina.
PH12016500057A1 (en) Novel indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
BR112012029647A2 (pt) novos derivados de pirimidinas
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
IN2015DN00950A (es)
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors